Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
Conditions
Keywords
Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
Brief summary
This study will assess the safety of panitumumab, irinotecan and everolimus when given in combination to treat advanced colorectal cancer
Detailed description
This is an open label uncontrolled phase IB/II study to determine the maximum tolerated dose (MTD) and assess the efficacy of everolimus, irinotecan and panitumumab when given in combination for patients with metastatic colorectal cancer and KRAS wild-type (WT). Patients with metastatic colorectal cancer (mCRC) that have failed fluorouracil based first line therapy will be included. It is anticipated that approximately 50 patients will be enrolled over a period of 24 months
Interventions
DRUGPanitumumab
Panitumumab 6mg/kg IV every 14 days
DRUGIrinotecan
Irinotecan 200mg/m2 IV every 14 days
DRUGEverolimus
Everolimus daily po (dosage varies with cohort)
Sponsors
Amgen
Novartis
The Queen Elizabeth Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 18 years * Histological diagnosis of colorectal cancer that is KRAS wild type * Metastatic disease not amenable to resection * Measurable disease as assessed by CT scan using RECIST criteria * Received and failed fluoropyrimidine therapy * Radiographically documented disease progression per RECIST criteria * For phase 1b group only, ECOG PS 0-1 * For phase 2 group only, ECOG PS 0-2 * Adequate bone marrow function with haemoglobin \> 100 g/L, platelets \> 100 X 109/l; neutrophils \> 1.5 X 109/l within 7 days of enrolment * Adequate renal function, with calculated creatinine clearance \>40 ml/min (Cockcroft and Gault) within 7 days of enrolment * Adequate hepatic function with serum total bilirubin \< 1.25 X upper limit of normal range and ALT or AST\<2.5xULN (\<5xULN if liver metastases present) within 7 days of enrolment * Magnesium ≥ lower limit of normal within 7 days of enrolment. * Fasting serum cholesterol ≤ 7.75mmol/L AND fasting triglycerides ≤ 2.5 x ULN. Note: In case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication. * Life expectancy of at least 12 weeks * Negative pregnancy test ≤ 72 hours before commencing study treatment (women of childbearing potential only). * Written informed consent including consent for biomarker studies
Exclusion criteria
* Presence of KRAS mutation in tumour sample * For Phase 1b group only, patients with prior pelvic radiotherapy. * Systemic chemotherapy, immunotherapy, approved proteins/antibodies or any investigational agent within 4 weeks prior to commencing study treatment * Radiotherapy within 14 days of commencing study treatment. * Unresolved toxicities from prior systemic therapy or radiotherapy * Medical or psychiatric conditions that compromise the patient's ability to give informed consent or to complete the protocol * Prior treatment with drugs targeting EGFR such as cetuximab, panitumumab or erlotinib * Prior therapy with mTOR inhibitors (sirolimus, temsirolimus, everolimus) * Prior therapy with irinotecan * CYP3A4 enzyme inducing anti-convulsant medication ≤ 14 days prior to study treatment. * Ketoconazole ≤ 7 days before study treatment. * Uncontrolled diabetes mellitus defined by fasting glucose \>1.5 x ULN. * Known cirrhosis, chronic active hepatitis, or chronic persistent hepatitis * Patients with known interstitial lung disease or severely impaired lung function * Patients with active bleeding diatheses. * Any uncontrolled clinically significant cardiac disease, arrhythmias or angina pectoris * Active inflammatory bowel disease or other bowel disease causing chronic diarrhoea * Chronic treatment with immunosuppressives * Patients with a known history of HIV seropositivity * Patients who have any severe and/or uncontrolled medical conditions or infections * Untreated or symptomatic CNS metastases * Patients who have a history of another primary malignant disease * Pregnancy or lactation. * Women and partners of women of childbearing potential who are not using effective contraception.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose limiting toxicities | at end of cycle 2 (each cycle is 14 days) | To determine the maximum tolerated dose (MTD)of everolimus, irinotecan and panitumumab when given in combination for patients with Kras WT mCRC |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety & toxicity | Approximately 24 weeks | Safety and toxicity assessed weekly during the phase Ib component (as per NCI CTCAE version 3.0) and fortnightly during the phase II component |
| Response rate | Assessed every 6 weeks until disease progression | Objective tumour response as per RECIST criteria V1.0 |
| Progression free survival | Until disease progression, occurrence of new disease or death | — |
| Overall Survival | Assessed 3 monthly until death | — |
Countries
Australia
Outcome results
None listed